Lieping Chen Explained

Lieping Chen (; born 1960) is a Chinese-American immunologist and physician-scientist.

Chen was born in Fuzhou, and graduated with a medical degree from Fujian Medical College in 1982, a master's of science degree in immunology from Peking Union Medical College in 1986, and a doctorate in pathology and laboratory medicine from Drexel University in 1989. After completing postdoctoral research at the University of Washington, Chen was a research scientist at Bristol Myers Squibb until 1997. Subsequently, Chen worked for the Mayo Clinic. Chen began his teaching career at the Johns Hopkins University School of Medicine in 2004, and joined the Yale University School of Medicine in 2010. At Yale, Chen holds the United Technologies Corporation Professorship in Cancer Research.[1] [2]

Chen's research has led to the establishment of several companies, including the Amplimmune Biotechnology Company (which was acquired by MedImmune in 2013),[3] [4] NextCure,[5] [6] and Normunity.[7] [8] Since 2018, Chen has been a member of the scientific advisory board of Zai Laboratory.[9]

In 2014, Chen shared the William B. Coley Award for Distinguished Research in Tumor Immunology. In 2017, he was a joint recipient of the Warren Alpert Foundation Prize.[10] The following year, Chen was named a Giant of Cancer Care[11] and elected a member of Taiwan's Academia Sinica.[12] In 2021, he was elected a fellow of the American Association for Cancer Research[13] as well as the United States National Academy of Sciences.[14] [15] In 2022, Chen was elected to the Connecticut Academy of Science and Engineering.[16]

Notes and References

  1. News: LIEPING CHEN . 2 January 2024 . Asia-Pacific Vaccine and Immunotherapy Congress.
  2. News: Lieping Chen, MD, PhD . 2 January 2024 . Yale Cancer Center.
  3. News: Distinguished Immunobiologist Lieping Chen Joins Yale Cancer Center . 2 January 2024 . 10 June 2010 . Yale Cancer Center.
  4. News: Former Mtech Maryland Industrial Partnerships Funding Recipient Amplimmune Acquired by MedImmune for $500 Million . 2 January 2024 . A. James Clark School of Engineering . 27 August 2013.
  5. News: Gregg . Aaron . New Germantown biotech nets $67 million from investors . 2 January 2024 . Washington Post . 8 January 2016.
  6. News: Lieping Chen, M.D., Ph.D. Chair . 2 January 2024 . NextCure.
  7. News: Wu . Lei Lei . PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tumors . 2 January 2024 . Endpoints News . 25 October 2022.
  8. News: Fider . Ben . With new startup, immunotherapy pioneer Lieping Chen tries to turn ‘cold’ tumors ‘hot’ . 2 January 2024 . BioPharma Dive . 25 October 2022.
  9. News: Lieping Chen, M.D., Ph.D. . 2 January 2024 . Zai Laboratory.
  10. News: Cancer immunologist Lieping Chen joins Ludwig Oxford as a Visiting Professor . 2 January 2024 . University of Oxford . 21 May 2021.
  11. News: IMMUNO-ONCOLOGY, INCLUDING CELL-BASED THERAPIES Lieping Chen, MD, PhD Codirector, Cancer Immunology Program, Yale Cancer Center . 2 January 2024 . Giants of Cancer Care . 2018.
  12. News: Lieping Chen . 2 January 2024 . Academia Sinica.
  13. News: LIEPING CHEN, MD, PHD Yale University School of Medicine New Haven, Connecticut . 2 January 2024 . American Association for Cancer Research . 2021.
  14. News: Yale Cancer Center’s Dr. Lieping Chen Elected to Prestigious National Academy of Sciences . 2 January 2024 . OncLive . 17 May 2021.
  15. News: Lieping Chen Yale University . 2 January 2024 . United States National Academy of Sciences . 2021.
  16. News: LIEPING CHEN . 2 January 2024 . Connecticut Academy of Science and Engineering.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lieping Chen".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.